Patient characteristics and response
| Factor . | MDS-EB2 (n = 202) . | WHO AML (n = 769) . | All (N = 971) . | P (MDS-EB2 vs WHO AML) . |
|---|---|---|---|---|
| Age, y | .36 | |||
| Mean | 62 | 63 | 62 | |
| Range | 22-85 | 18-91 | 18-91 | |
| Performance status | .85 (0-1 vs 2-4) | |||
| 0-1 | 159 (79) | 598 (78) | 757 (78) | |
| 2-4 | 43 (21) | 171 (22) | 214 (22) | |
| Disease status | ||||
| De novo | 179 (89) | 553 (72) | 732 (75) | |
| Secondary | 23 (11) | 216 (28) | 239 (25) | |
| Subcategory of secondary | ||||
| Prior marrow documenting MDS or MPN (AHD) | NA | 123 (16) | 123 (13) | NA |
| Prior cytotoxic therapy, no AHD | 23 (11) | 72 (9) | 95 (10) | .53 |
| Both AHD and prior cytotoxic therapy | NA | 21 (3) | 21 | NA |
| Morphologic blasts, % | <.001 | |||
| Mean | 14 | 45 | 34 | |
| Range | 10-19.8) | 0-100 | 0-100 | |
| ELN 2017 risk group | <.001 | |||
| Favorable | 11 (5) | 189 (25) | 200 (21) | <.0001 |
| Intermediate | 98 (49) | 293 (38) | 391 (40) | .009 |
| Adverse | 89 (44) | 274 (36) | 363 (37) | .03 |
| Unknown | 4 (2) | 13 (2) | 17 (2) | .76 |
| Induction intensity | .038 | |||
| High | 137 (68) | 577 (75) | 714 (75) | |
| Low | 65 (32) | 192 (25) | 257 (26) | |
| CR | ||||
| CRMRD− | 59 (29) | 359 (47) | 418 (43) | <.001 |
| CR or CRi | 117 (58) | 530 (69) | 647 (67) | .0043 |
| Treatment with allogeneic HCT | 90 (45) | 270 (35) | 960 (37) | .02 |
| Factor . | MDS-EB2 (n = 202) . | WHO AML (n = 769) . | All (N = 971) . | P (MDS-EB2 vs WHO AML) . |
|---|---|---|---|---|
| Age, y | .36 | |||
| Mean | 62 | 63 | 62 | |
| Range | 22-85 | 18-91 | 18-91 | |
| Performance status | .85 (0-1 vs 2-4) | |||
| 0-1 | 159 (79) | 598 (78) | 757 (78) | |
| 2-4 | 43 (21) | 171 (22) | 214 (22) | |
| Disease status | ||||
| De novo | 179 (89) | 553 (72) | 732 (75) | |
| Secondary | 23 (11) | 216 (28) | 239 (25) | |
| Subcategory of secondary | ||||
| Prior marrow documenting MDS or MPN (AHD) | NA | 123 (16) | 123 (13) | NA |
| Prior cytotoxic therapy, no AHD | 23 (11) | 72 (9) | 95 (10) | .53 |
| Both AHD and prior cytotoxic therapy | NA | 21 (3) | 21 | NA |
| Morphologic blasts, % | <.001 | |||
| Mean | 14 | 45 | 34 | |
| Range | 10-19.8) | 0-100 | 0-100 | |
| ELN 2017 risk group | <.001 | |||
| Favorable | 11 (5) | 189 (25) | 200 (21) | <.0001 |
| Intermediate | 98 (49) | 293 (38) | 391 (40) | .009 |
| Adverse | 89 (44) | 274 (36) | 363 (37) | .03 |
| Unknown | 4 (2) | 13 (2) | 17 (2) | .76 |
| Induction intensity | .038 | |||
| High | 137 (68) | 577 (75) | 714 (75) | |
| Low | 65 (32) | 192 (25) | 257 (26) | |
| CR | ||||
| CRMRD− | 59 (29) | 359 (47) | 418 (43) | <.001 |
| CR or CRi | 117 (58) | 530 (69) | 647 (67) | .0043 |
| Treatment with allogeneic HCT | 90 (45) | 270 (35) | 960 (37) | .02 |
Data presented as n (%) unless otherwise indicated.
AHD, antecedent hematologic disorder; CRi, CR with incomplete hematologic recovery; CRMRD−, CR without measurable residual disease.